Stock Analysis on Net
Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$17.99

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Bristol-Myers Squibb Co. for $17.99, or

  • get full access to the entire website for at least 3 months from $49.99.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Income Statement

Bristol-Myers Squibb Co., consolidated income statement

US$ in millions

Microsoft Excel LibreOffice Calc
12 months ended: Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Net product sales
Alliance and other revenues
Revenues
Cost of products sold, excludes amortization of acquired intangible assets
Gross margin
Marketing, selling and administrative
Research and development
IPRD charge, MyoKardia acquisition
Amortization of acquired intangible assets
Operating income (loss)
Interest expense
Contingent consideration
Royalties and licensing income
Equity investment gains (losses)
Integration expenses
Provision for restructuring
Litigation and other settlements
Transition and other service fees
Investment income
Reversion excise tax
Divestiture gains
Intangible asset impairment
Pension and postretirement
Acquisition expenses
Loss on debt redemption
Other
Other income (expense), net
Earnings (loss) before income taxes
Provision for income taxes
Net earnings (loss)
Noncontrolling interest
Net earnings (loss) attributable to BMS

Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).

Income statement item Description The company
Revenues Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Bristol-Myers Squibb Co.’s revenues increased from 2018 to 2019 and from 2019 to 2020.
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Bristol-Myers Squibb Co.’s operating income (loss) increased from 2018 to 2019 but then decreased significantly from 2019 to 2020.
Earnings (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Bristol-Myers Squibb Co.’s earnings (loss) before income taxes decreased from 2018 to 2019 and from 2019 to 2020.
Net earnings (loss) attributable to BMS The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Bristol-Myers Squibb Co.’s net earnings (loss) attributable to BMS decreased from 2018 to 2019 and from 2019 to 2020.